BioXcel Therapeutics, Inc. (BTAI)
| Market Cap | 33.03M +227.0% |
| Revenue (ttm) | 642,000 -71.7% |
| Net Income | -69.90M |
| EPS | -5.73 |
| Shares Out | 27.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 565,031 |
| Open | 1.220 |
| Previous Close | 1.240 |
| Day's Range | 1.190 - 1.260 |
| 52-Week Range | 1.010 - 8.080 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+1,785.25%) |
| Earnings Date | May 22, 2026 |
About BTAI
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmede... [Read more]
Full Company ProfileFinancial Performance
In 2025, BioXcel Therapeutics's revenue was $642,000, a decrease of -71.67% compared to the previous year's $2.27 million. Losses were -$69.90 million, 17.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 1,785.25% from the latest price.
News
BioXcel Therapeutics Transcript: Investor update
IGALMI is poised for a major market expansion as the first FDA-approved at-home treatment for acute agitation in bipolar and schizophrenia, with strong support from physicians, patients, and payers. Launch preparations target a Q1 2027 rollout, with ongoing efforts to secure payer access, educate prescribers, and explore partnerships.
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn.
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
BioXcel Therapeutics enrolls first patients in BXCL501 trial
BioXcel Therapeutics (BTAI) announced the enrollment of the first patients in a U.S. Department of War-funded Phase 2a clinical trial evaluating BXCL501 for the treatment of acute stress reactions, al...
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War ...
BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $5 from $6 and keeps a Buy rating on the shares. The firm cites the company’s recent and
BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA
BioXcel Therapeutics (BTAI) announced that the FDA has accepted its supplemental new drug application, or sNDA, for approval of Igalmi for at-home use in the acute treatment of agitation associated
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outp...
BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)
Reports Q4 revenue $256,000, consensus $151,520. “2025 was a successful year for our Company, setting the stage for the potential label expansion of IGALMI in the at-home setting and continuing
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia
BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of BioXcel Therapeutics (BTAI) with a Buy rating and $17 price target citing the company’s “differentiated” at-home agitation franchise, expanding BXCL501 neuropsyc...
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative m...
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative m...
BioXcel price target lowered to $6 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $6 from $10 and keeps a Buy rating on the shares. The firm cites the recent and anticipated
BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
BioXcel Therapeutics (BTAI) announced positive topline results from a Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use ...
BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
BioXcel Therapeutics (BTAI) announced positive topline results from a Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use ...
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL...
BioXcel Therapeutics Transcript: Status update
Acute agitation in Alzheimer's dementia is a major unmet need, with current treatments relying on off-label sedatives that pose safety risks. BXCL501, a dexmedetomidine oral film, demonstrated rapid, well-tolerated efficacy in phase III trials and could significantly reduce caregiver burden and emergency visits.
BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia
BioXcel Therapeutics (BTAI) will host a virtual key opinion leader roundtable on Friday, February 27, from 2:00 to 3:00 p.m. EST. The event is a continuation of the Company’s awareness
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia
Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer's dementia Large patient population affected by Alzhei...
BioXcel completes updated market opportunity assessment for Igalmi
BioXcel Therapeutics (BTAI) announced the completion of an updated market opportunity assessment for Igalmi for acute agitation associated with bipolar disorders or schizophrenia in the at-home settin...
BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi
BioXcel Therapeutics (BTAI) announced it submitted a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration, FDA, for the acute treatment of agitation associated with bipola...
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI ® Submission timeline supports potential ap...
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary ...
BioXcel Therapeutics appoints Pavao as acting CCO
BioXcel Therapeutics (BTAI) announced the advancement of its commercial planning for IGALMI in the at-home setting. As part of this, Mark Pavao has joined as Acting Chief Commercial Officer, CCO,